Is AbbVie stock a good buy?

AbbVie stock has received a consensus rating of buy. The average rating score is and is based on 31 buy ratings, 14 hold ratings, and 2 sell ratings. What was the 52-week low for AbbVie stock? The low in the last 52 weeks of AbbVie stock was 130.96. According to the current price, AbbVie is 114.73% away from the 52-week low.

When will abbv start trading ex-dividend?

ABBV Regular Dividend: ABBV will begin trading ex-dividend on 07/13/23 with a $1.48 dividend payable to shareholders of record as of 07/14/23.

What happened to AbbVie?

No significant news for in the past two years. AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including...

What does AbbVie do?

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson's, and alzheimer's disease.